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Abstract
Background: Cholesterol-lowering therapy with statins is recommended in established cardiovascular disease (CVD)
and should be considered for patients at high cardiovascular risk. We surveyed statin treatment before first-time
myocardial infarction in clinical practice compared to current guidelines, in patients with and without known CVD
in primary care clinics with general practitioners (GPs) on short-term contracts vs. permanent staff GPs.
Methods: A total of 931 patients (345 women) in northern Sweden were enrolled in the study between November
2009 and December 2014 and stratified by prior CVD, comprising angina pectoris, revascularisation, ischaemic
stroke or transitory ischaemic attack, or peripheral artery disease. Primary care clinics were classified by the
proportion of GP salaries that were paid to GPs working on short-term contracts: low (0–9 %), medium (10–39 %),
or high (≥40 %). We used logistic regression to identify determinants of statin treatment.
Results: Among patients with prior CVD, only 34.5 % received statin treatment before myocardial infarction. The
probability of statin treatment decreased with age (≥70 years OR 0.30; 95 % CI 0.13–0.66) and female gender
(OR 0.39; 95 % CI 0.20–0.78) but increased in patients with diabetes (OR 3.52; 95 % CI 1.75–7.08). Among patients
with prior CVD, the type of primary care clinic was not predictive of statin treatment. In the entire study cohort,
17.3 % of patients were treated with statins; women < 70 years old were more likely to receive statin treatment
than women ≥70 years old (OR 3.24; 95 % CI 1.64–6.38), and men ≥70 years old were twice as likely to be treated
with statins than women of the same age (OR 2.22; 95 % CI 1.31–3.76) after adjusting for diabetes and CVD. Overall,
patients from clinics with predominantly permanent staff GPs received statin therapy less frequently than those
with GPs on short-term contracts.
Conclusions: In patients with prior CVD we found considerable under-treatment with statins, especially among
women and the elderly. Methodologies for case findings, recall, and follow-up need to be improved and
implemented to reach the goals for CVD prevention in clinical practice.
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Background
Statin treatment reduces cardiovascular (CV) morbidity
and mortality in patients at increased risk of CV events [1–
5]. The Scandinavian simvastatin survival study group (4S)
was the first to report decreased CV mortality from statin
treatment [5]. Several different statins have since become
available at low cost as generic drugs. The pharmacological
mechanism common to all statins is inhibition of the rate
controlling enzyme Hydroxymethylglutaryl-CoA reductase
in cholesterol synthesis [6], whereas the relative efficiency
depends on the dose and type of statin [7]. The most
commonly reported adverse effects related to statins
are muscle symptoms, and asymptomatic liver enzyme
elevation [8–12]. The risk of incident diabetes is
slightly increased by statins, but it is outweighed by the
total CV risk reduction in treated patients [9, 13, 14].
Treatment of patients with previous cardiovascular
disease (CVD) (i.e., secondary prevention) targets
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patients at very high CV risk, in contrast to treatment of
persons apparently free from disease (i.e., primary pre-
vention) [15]. Other patients with a very high or high
total CV risk are those with diabetes (type 2 diabetes or
type 1 diabetics with microalbuminuria), chronic kidney
disease, or very high levels of individual risk factors [15,
16]. Statin treatment should be offered to women with
the same therapeutic targets as men [1, 15, 17, 18]. Pre-
vious trials have had positive results with statin therapy
among elderly patients [1, 19, 20]. In patients with estab-
lished CVD, and there is evidence of the same relative
risk reduction up to 75–80 years of age [21, 22].
A scoring algorithm can be used to estimate CV risk
in patients without previously diagnosed CVD, e.g. The
Swedish SCORE chart for cardiovascular risk (10-year
risk of CV death is calculated from age, sex, smoking
status, systolic blood pressure, and total serum choles-
terol) [23], and several algorithms have been put forth
[24–27]. The restriction of SCORE to ages 40–65 years
is a problem because patients over 65 years of age are
also eligible for preventive drug treatment. A SCORE
value ≥5 % is proposed to be the cut-off for defining
patients at high CV risk who could benefit from lipid-
lowering drug treatment [28, 29].
To identify patients at increased risk of CVD, the par-
ticipation of general practitioners (GPs) is crucial [29],
but the implementation of treatment guidelines in prac-
tice may still be insufficient. Inadequate knowledge, time
constraints, and insufficient patient compliance are
barriers to implementing guidelines on CVD prevention
[30–32]. Concerns have also been raised regarding over-
estimating risk and the consequences of overusing
pharmacotherapy in national populations [33–35].
Lower adherence to therapy is associated with the pa-
tient’s understanding of risk in relation to disease [36],
the provider-patient relationship, and continuity of care
[37]. However, before barriers to implementation of risk-
adjusted prevention in primary care can be dealt with,
they must be identified [34, 35, 38–40]. What still re-
mains to bridge, is the gap between clinical practice and
the optimal treatment with statins according to scientific
evidence. Therefore, we designed a population-based
survey of patients hospitalised with first-time myocardial
infarction (MI). The primary aim of this study was to
assess treatment with statins prior to first-time MI, in
patients with and without previously diagnosed CVD.
Another aim was to assess treatment differences re-




We conducted a population-based survey in the region
of Jämtland Härjedalen, northern Sweden, which has
one central cardiology unit and 21 primary care clinics
run by the regional health authorities. Roughly half of
the patients live in rural communities, with primary care
clinics available in each. Participating patients were hos-
pitalised with first-time MI type 1 according to the uni-
versal definition [41, 42] between November 26, 2009,
and December 31, 2014. The patients were identified
from a population-based secondary prevention study
after acute coronary syndrome (ACS), “The Nurse-Based
Age Independent Intervention to Limit Evolution of Dis-
ease After Acute Coronary Syndrome (NAILED ACS)
Risk Factor Trial”; the outline of this study was pub-
lished previously [43]. Baseline medical data and demo-
graphics were recorded during the initial hospitalisation
by experienced nursing staff. The patients were stratified
by prior CVD, which comprised angina pectoris, revas-
cularisation (coronary artery bypass grafting or percu-
taneous coronary intervention), ischaemic stroke or
transitory ischaemic attack (TIA), or peripheral artery
disease (PAD). PAD comprised leg artery disease, a sten-
osing lesion of the carotid, or atherosclerotic aneurysm.
The 10-year risk of fatal CV events was manually esti-
mated from the pre-existing baseline data for patients
40–65 years of age at study entry without prior CVD or
diabetes, according to the Swedish SCORE chart in use
during the study period [23]. The primary care clinics
within the study area were classified according to the
percent of salaries allocated to GPs working on short-
term contracts vs. salaries paid to GPs on the permanent
staff between 2010 and 2014. This data was provided by
the regional health authorities.
Statistical analysis
Patient characteristics are presented as proportions or
means. We used the chi-squared test or Fisher’s exact
test, as appropriate, to compare proportions and the
two-sided Student’s t-test to compare means. In a trend
analysis, age was stratified in 10-year intervals. In the re-
gression model, age was dichotomised at 70 years, the
mean age of the study population. Primary care clinics
were stratified into three levels according to the primary
care clinics’ use of GPs on short-term contracts, with ap-
proximately one-third of study patients in each level:
low (0–9 %), medium (10–39 %), and high (≥40 %)
short-term clinics. We used univariate logistic regression
with patients stratified by prior CVD to identify patient
determinants that were predictive of statin treatment. In a
multivariable logistic model, we included the interaction
term “age ≥70 years × female gender” with age ≥70 years,
female gender, diabetes, and prior CVD as covariates. The
SCORE variable was not included in the regression model
due to bidirectional causality between statin treatment
and the subsequent SCORE value. In an interaction model
of age and gender, we calculated ORs for statin treatment
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adjusted for diabetes and prior CVD. The level of signifi-
cance was set at p < 0.05. Sample size calculations were
performed using WINPEPI, version 11.54 [44], and all




The study included 931 patients (345 women) with a
first-time MI. The mean patient age was 74.7 years in
women and 68.2 years in men. Most study patients
(60.5 %) were current or previous manual workers. A
complete background of the study population was de-
scribed elsewhere [43].
Among the complete study sample, 4.1 % reported
prior revascularisation and 5.6 % previous ischaemic
stroke or TIA. Current diagnoses of angina pectoris,
hypertension, diabetes, and PAD were reported by
11.7 %, 54.9 %, 18.5 %, and 2 % of study patients, re-
spectively (Table 1). A total of 17.3 % of patients were
being treated with statins at the time of admission to the
hospital. Prior CVD was diagnosed in 166 of 931 pa-
tients (17.8 %) (Table 1). Patients with prior CVD were
older, less often current smokers, more often diagnosed
with diabetes, and received CV drugs more frequently.
The low density lipoprotein (LDL) cholesterol levels were
3.0 (1.1 SD) and 3.3 (1.1 SD) mmol/L in patients with and
without prior CVD, respectively (p = 0.010; Table 1).
Simvastatin was the most prescribed statin, with 139
of the 161 patients on statins (86.3 %) receiving it, at a
median dose of 20 mg in men and women. Twenty pa-
tients received atorvastatin. Only nine patients were
treated with other statins or lipid-lowering drugs (bezafi-
brat, ezetimib) as single or combination treatment. High
statin doses were uncommon; 6/161 patients were
treated with 80 mg of simvastatin or atorvastatin. Sixty-
two percent of the study patients were registered to a
primary care clinic where ≥10 % of GPs served on short-
term contracts (Table 2).
Key findings
Among patients with prior CVD, 34.5 % were on statin
treatment before admission for MI compared to 13.6 %
of patients with no prior CVD (p < 0.001). Diabetes pa-
tients were treated with statins more often than non-
diabetics. Within the entire study cohort, patients from
clinics with predominantly permanent staff GPs received
statin therapy less frequently than those with GPs on
short-term contracts. Among patients with a risk
SCORE value ≥5 % (age 40–65 years without prior CVD
or diabetes), only 4.3 % (3/70) received statin treatment,
compared to 7.6 % (11/144) of patients with a risk
SCORE value <5 % (Table 3).
Patients with prior CVD
In prior CVD patients, treatment with statins decreased
with each 10-years age interval (p < 0.001 for trend;
Table 4, and Additional file 1). Decreasing statin treat-
ment with higher age was also observed after stratifica-
tion according to the type of primary care clinic: low
short-term (p = 0.028 for trend); medium to high short-
term (p = 0.002 for trend). Crude ORs for statin treat-
ment in patients ≥70 years and female patients were
both inversely correlated with statin treatment, and the
probability of statin treatment was not significantly dif-
ferent between types of primary care clinics (Table 5). In
contrast to statins, treatment with other CV drugs, such
as angiotensin-converting enzyme (ACE) inhibitors,
angiotensin receptor blockers (ARBs), beta-blockers, cal-
cium channel blockers, and acetylsalicylic acid, did not
decline with age.
Analyses including the entire patient cohort: Statin
treatment by gender and age
The adjusted logistic model revealed a strong inter-
action between age and female gender with adjusted
ORs for statin treatment (95 % CI) of 1.29 (0.79–2.11) for
age ≥70 years; 1.88 (1.02–3.50) for female gender; and
0.24 (0.11–0.54) for age ≥70 × female gender, with positive
ORs for diabetes and prior CVD (Table 6). Among
women, the probability of statin treatment was approxi-
mately three-times as high in women <70 years of age
compared to women ≥70 years of age. In patients ≥70 years
of age, the probability of statin treatment in men was ap-
proximately twice as high as in women after adjusting for
prior CVD and diabetes (female patients ≥70 years old
served as a reference; Table 7).
Discussion
Only one-third of patients with a first-time MI and pre-
viously diagnosed CVD were being treated with statins
before the MI, despite guidelines that support active
treatment of patients with known CVD [15, 29, 45]. In
prior CVD patients, increasing age and female gender
were associated with a lower probability of statin treat-
ment, whereas diabetes was associated with a higher
probability of statin treatment.
Our results revealed barriers to statin treatment for
secondary prevention. The mean LDL cholesterol levels
(3.0 mmol/L) exceeded the target level for high-risk pa-
tients according to the former and present European
guidelines for CVD prevention in clinical practice [29, 46].
The Swedish guidelines for treatment of CVD during
the study period recommended a target LDL cholesterol
level <2.5 mmol/L in patients at very high CV risk [47].
Reasons for the underuse of statin treatment may be sev-
eral: a lack of secondary prevention programmes; patients’
diminishing adherence to therapy over time; experienced
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or expected side effects of statins; and insufficient adher-
ence to clinical guidelines among physicians.
The quality of CV risk management is associated
with routines for case finding, patient follow-up, and
CVD risk assessment integrated into the electronic
medical record system [48]. Follow-up programmes
delivered in primary care or as a nurse-based telephone
follow-up have shown promising results with im-
proved CV risk factors and treatment for coronary
disease [43, 49–51].
Adherence to medication is associated with the ac-
cess to and continuity of healthcare [37]. Within our
study area, the continuity of primary care was im-
paired due to lack of GPs working as permanent staff.
However, fewer patients received statin treatment at
primary care clinics with predominantly permanent
staff GPs, for unknown reasons.
The initial CVD event among our study patients may
have occurred several years before the first-time MI. A
2-year adherence to statin therapy of 36.1 % for chronic
coronary disease has been reported among elderly pa-
tients, and it is even less for primary prevention [52].
Concerns about side effects is associated with low ad-
herence to drug therapy [53, 54]. Consequently, discon-
tinuation of statins within 6 months after initiating
Table 2 Primary care clinics by proportion of GP salaries paid to
GPs working on short-term contracts
Proportion of GP salaries






Low (0–9 %) 11 353 (38 %)
Medium (10–39 %) 6 333 (36 %)
High (≥40 %) 4 245 (26 %)
Total 21 931 (100 %)
Table 1 Characteristics of patients admitted for first-time myocardial infarction
Characteristic Total n = 931 Prior CVD n = 166 (17.8 %) No prior CVD n = 765 (82.2 %) p
Age at admission to hospital, mean (SD) 70.6 (12.2) 78.3 (9.4) 68.9 (12.1) <0.001
Female gender 345 (37.1 %) 71/166 (42.8 %) 274/765 (35.8 %) 0.093
Manual worker 531 (60.5 %) 96/151 (63.6 %) 435/727 (59.8 %) 0.392
Current smoker 198 (21.7 %) 21/159 (13.2 %) 177/755 (23.4 %) 0.004
Systolic blood pressure, mmHg, mean (SD) (67 missing)a 142 (18.4) 143 (18.7) 142 (18.3) 0.517
Diastolic blood pressure, mmHg, mean (SD) (67 missing)a 81 (11.2) 78 (12.5) 82 (10.7) <0.001
Total cholesterol, mmol/L, mean (SD) (44 missing) 5.2 (2.2) 4.9 (1.3) 5.3 (2.4) 0.064
LDL cholesterol, mmol/L, mean (SD) (56 missing) 3.2 (1.1) 3.0 (1.1) 3.3 (1.1) 0.010
ST-elevation myocardial infarction 321 (34.5 %) 36/166 (21.7 %) 285/765 (37.3 %) <0.001
Past medical history
Revascularisation (CABG/PCI) 38 (4.1 %) 38/166 (22.9 %) NA -
Ischaemic stroke or TIA 52 (5.6 %) 52/166 (31.3 %) NA -
Present conditions
Angina pectoris, current diagnosis 109 (11.7 %) 109/166 (65.7 %) NA -
Peripheral artery disease (PAD) 19 (2.0 %) 19/166 (11.4 %) NA -
Hypertension, current diagnosis 511 (54.9 %) 124/166 (74.7 %) 387/765 (50.6 %) <0.001
Diabetes, current diagnosis 172 (18.5 %) 49/166 (29.5 %) 123/765 (16.1 %) <0.001
Medication at admission to hospital
ACE inhibitor/ARB 292 (31.5 %) 69/165 (41.8 %) 223/763 (29.2 %) <0.002
Beta-blockers 265 (28.6 %) 89/165 (53.9 %) 176/762 (23.1 %) <0.001
Calcium channel blockers 207 (22.4 %) 60/164 (36.6 %) 147/762 (19.3 %) <0.001
Diuretics 248 (26.8 %) 72/165 (43.6 %) 176/762 (23.1 %) <0.001
Long-acting nitroglycerine 49 (5.3 %) 45/165 (27.3 %) 4/763 (0.5 %) <0.001
Statins 161 (17.3 %) 57/165 (34.5 %) 104/763 (13.6 %) <0.001
Acetylsalicylic acid 222 (23.9 %) 112/165 (67.9 %) 110/763 (14.4 %) <0.001
ACE angiotensin-converting-enzyme inhibitor, ARB angiotensin-receptor blocker, CABG coronary artery bypass grafting, CVD cardiovascular disease, a composite of
diagnoses including angina pectoris, prior revascularisation, ischaemic stroke/TIA, or PAD (leg artery disease, a stenosing lesion of the carotid or atherosclerotic
aneurysm), Current diagnosis of diabetes is type 1 or type 2. LDL low density lipoprotein, PCI percutaneous coronary intervention, TIA transitory ischaemic attack,
NA not applicable
aLast representative blood pressure before admission to hospital
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therapy has been attributed to negative statin-related
news reports in public media [55].
Discontinuation of previously initiated statin therapy
due to side effects or negative public media reporting
may have contributed considerably to the low number of
patients receiving statins for secondary prevention.
Follow-up of patients remains essential, even in patients
with symptoms attributable to drug treatment, as most
patients that are rechallenged with a statin are still able
to tolerate statins long-term [56].
The usage of clinical guidelines in clinical practice is
known to be incomplete [30, 57, 58], and the adoption
of new treatment targets may be a slow process in gen-
eral practice [35, 38, 39]. Patients’ understanding of the
CV risk concept may also be an important barrier for
preventive treatment [36].
Because we recruited patients of all ages, comparisons
to population-based cohorts from restricted age seg-
ments should be made with caution. According to the
“Irish Longitudinal Study on Ageing” [59], the propor-
tion of patients undergoing statin treatment was 68.8 %
for patients with known CVD, 57.4 % for diabetic pa-
tients, and 19.7 % when SCORE of risk was ≥5 %. Statin
treatment in 49.1 % of our diabetic patients was possibly
related to a twice yearly follow-up programme for dia-
betics. The modest rate of statin treatment in patients
with prior CVD (34.5 %) may have been related to a lack
of follow-up for CVD patients in our study area.
Women ≥70 years of age were less frequently on
current statin treatment than men in the same age group
or younger women possibly due to combinations of
several causes. Female gender and age (>80 years) are
independent risk factors for statin-associated muscle
symptoms [12, 60]. A possible interaction between age
and gender in relation to discontinuation of statin ther-
apy should be researched further.
Awareness of personal CV risk profiles may be import-
ant for adherence to medication. In a recent survey
conducted in women, underestimation of CV risk was
common, with age as the most significant predictor [61].
In our cohort, only 3/70 patients with a SCORE ≥5 %
for CV risk received statin treatment. Apparently, CV
risk assessment by the SCORE chart was not imple-
mented in clinical practice during the study period.
The reasons for the lower proportion of overall statin
treatment among patients from primary care clinics with
more permanent staff GPs (low short-term clinics) are
not clear based on the study data. To provide more sup-
porting evidence concerning the prescription preferences
of GPs at different experience levels, a qualitative study
approach could have been applied, but it was beyond the
scope of our present study.
Future aspects
The gap between CVD guidelines and clinical practice
has been reported previously [62, 63], but the age- and
gender-related aspects of this gap has not gained suffi-
cient attention. To bridge this gap it is necessary to de-
velop and implement procedures for case finding, recall,
Table 3 Statin treatment prior to first-time myocardial infarction
according to patient and primary care clinic characteristics (n= 928)
Characteristics Treatment with statins p
Patient characteristics
Female gender 57/344 (16.6 %) 0.630
Male gender 104/584 (17.8 %)
Age <70 years 67/433 (15.5 %) 0.158
Age ≥70 years 94/495 (19.0 %)




Prior cardiovascular disease (CVD) 57/165 (34.5 %) <0.001
No prior CVD 104/763 (13.6 %)
Diabetes, current diagnosis 84/171 (49.1 %) <0.001
Diabetes not recorded 77/757 (10.2 %)
SCORE <5 % 11/144 (7.6 %) 0.728
SCORE ≥5 % - <10 % 3/55 (5.5 %)
SCORE ≥10 % 0/15 (0.0 %)
Proportion of GP salaries paid to GPs
working on short-term contracts
0–9 % (low short-term clinics) 48/351 (13.7 %) 0.047
10–39 % (medium) 54/255 (21.2 %)
≥ 40 % (high) 59/322 (18.3 %)
CVD is a composite of diagnoses including angina pectoris, prior
revascularisation, ischaemic stroke/transitory ischaemic attack, or peripheral
artery disease (PAD). PAD comprised leg artery disease, a stenosing lesion of
the carotid or atherosclerotic aneurysm. Current diagnosis of diabetes includes
diabetes of type 1 or type 2. SCORE: Systematic Coronary Risk Estimation,
assessed in patients aged 40–65 years without prior CVD or diabetes. Three
cases were missing data on statins and 53 on employment status
Table 4 Statin treatment prior to first-time myocardial infarction
according to age (n = 928)
Age at hospital
admission, years
Prior CVD (n = 165) No prior CVD
(n = 763)
≤49 1/1 (100 %) 4/45 (8.9 %)
50–59 2/4 (50 %) 13/117 (11.1 %)
60–69 15/26 (57.7 %) 32/240 (13.3 %)
70–79 20/53 (37.7 %) 36/204 (17.6 %)
80–89 18/66 (27.3 %) 17/126 (13.5 %)
≥90 1/15 (6.7 %) 2/31 (6.5 %)
Total 57/165 (34.5 %) 104/763 (13.6 %)
CVD cardiovascular disease, a composite of diagnoses including angina
pectoris, prior revascularisation, ischaemic stroke/transitory ischaemic attack,
or peripheral artery disease (PAD). PAD comprised leg artery disease, a
stenosing lesion of the carotid, or atherosclerotic aneurysm. Prior CVD,
p < 0.001 for trend. No prior CVD, p = 0.438 for trend
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and follow-up of patients with established CVD [64, 65].
Such procedures should be integrated into electronic
medical records as much as possible. Algorithms for
CV risk assessment should be fully implemented in
clinical practice, since single risk factor assessment
could lead to false conclusions of CV risk, with po-
tential overuse of drugs.
Limitations
We enrolled MI patients admitted to the hospital; there-
fore, our results are not fully comparable to findings in
community-based cohorts. Data on the time of the initi-
ation of statin treatment, discontinuation of treatment,
and side effects were not available. In most patients, an-
gina pectoris, one of the components of the CVD diag-
nosis, was determined as a clinical diagnosis and not
evaluated by coronary angiography. In medical practice,
treatment decisions are often based on clinical risk
evaluation, and invasive procedures are not always re-
quired or justified [66, 67]. In patients aged 40–65 years,
the SCORE of CV risk [23] was determined from base-
line data a posteriori. Due to a bidirectional relationship
between statin therapy and the SCORE value, in patients
achieving lower cholesterol levels after initiation of
statins, the SCORE variable was not included in the
regression model of determinants of statin treatment.
Pre-treatment cholesterol levels were not available.
A post hoc calculation of sample sizes required to de-
tect a difference in statin treatment with respect to pri-
mary care clinics’ use of short-term GPs, stratified by
prior CVD, revealed a need for a larger sample size to
reach a power of 0.8 at a significance level of 0.05. Thus,
the study had insufficient power to detect a between-
clinic difference in the use of statins after stratification
by prior CVD.
We compared primary care clinics by the use of GPs
working on short-term contracts vs. permanent staff GPs
as a substitute for a measurement on the provider-patient
level. Direct measurement at the level of care was not pos-
sible to obtain within the resources of this study.
Non-surviving patients due to out-of-hospital cardiac ar-
rest were not included in the study, which limits the results
to being applied to patients alive after a first-time MI.
Conclusions
In patients with prior CVD we found considerable
under-treatment with statins, especially among women and
the elderly. In the entire study cohort, women ≥70 years of
age had lower probability of statin treatment than men of
the same age or younger women, after adjusting for dia-
betes and prior CVD. Overall, patients from clinics with
predominantly permanent staff GPs received statin therapy
Table 5 Crude odds ratios (ORs) for statin treatment before first-time myocardial infarction stratified by cardiovascular disease (CVD)
(n = 928)
Characteristics Prior CVD n = 165 No prior CVD n = 763
Patient characteristics OR (95 % CI) p OR (95 % CI) p
Age ≥70 years at admission to hospital 0.30 (0.13–0.66) 0.003 1.30 (0.86–1.96) 0.222
Female gender 0.39 (0.20–0.78) 0.008 1.19 (0.78–1.82) 0.422
Diabetes 3.52 (1.75–7.08) <0.001 11.08 (6.97–17.62) <0.001
Proportion of GP salaries paid to GPs working on short-term contracts
0–9 % short-term Reference Reference
10–39 % short-term vs. 0–9 % 1.38 (0.61–3.14) 0.437 1.79 (1.07–2.98) 0.026
≥ 40 % to short-term vs. 0–9 % 2.02 (0.92–4.40) 0.078 1.23 (0.74–2.05) 0.425
CVD is a composite of diagnoses including angina pectoris, prior revascularisation, ischaemic stroke/transitory ischaemic attack, or peripheral artery disease (PAD).
PAD comprised leg artery disease, a stenosing lesion of the carotid, or atherosclerotic aneurysm. Current diagnosis of diabetes is type 1 or type 2
Table 6 Adjusted odds ratios (ORs) for statin treatment prior to
first-time myocardial infarction (n = 928)
Characteristic Adjusted OR (95 % CI) p
Age ≥70 years 1.29 (0.79–2.11) 0.305
Female gender 1.88 (1.02–3.50) 0.044
Age ≥70 years × female gender 0.24 (0.11–0.54) <0.001
Diabetes 8.55 (5.72–12.79) 0.001
Prior cardiovascular disease (CVD) 3.27 (2.08–5.13) <0.001
CVD is a composite of diagnoses: including angina pectoris, prior
revascularisation, ischaemic stroke/transitory ischaemic attack, or peripheral
artery disease (PAD). PAD comprised leg artery disease, a stenosing lesion of
the carotid, or atherosclerotic aneurysm. Current diagnosis of diabetes is type
1 or type 2
Table 7 Adjusted odds ratios (ORs) for statin treatment by age
and gender (n = 928)
Gender Age at admission for first-time myocardial infarction
<70 years OR (95 % CI) ≥70 years OR (95 % CI)
Male 1.72 (0.99–2.99) (n = 326) 2.22 (1.31–3.76) (n = 258)
Female 3.24 (1.64–6.38) (n = 107) 1.00 (n = 237)
Females ≥70 years of age served as the reference. ORs were adjusted for prior
cardiovascular disease (CVD) and diabetes. CVD is a composite of diagnoses:
including angina pectoris, prior revascularisation, ischaemic stroke/transitory
ischaemic attack, or peripheral artery disease (PAD). PAD comprised leg artery
disease, a stenosing lesion of the carotid, or atherosclerotic aneurysm.
Diabetes includes type 1 and type 2
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less frequently than those with GPs on short-term
contracts. Methodologies for case finding, recall, and
follow-up of CVD patients need to be improved and
implemented to achieve the goals for CVD prevention
in clinical practice.
Additional file
Additional file 1: Estimated probability of statin treatment (95 % CI) in
patients with prior cardiovascular disease by age. (JPG 19 kb)
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